Latest News

Proton pump inhibitors linked to neurological conditions


A new analysis of the FDA adverse events database (FAERS) has reported that use of proton pump inhibitors (e.g. omeprazole, rabeprazole, lansoprazole, pantoprazole) may be associated with a risk of neurological conditions, including hearing and visual impairment, memory loss, neuropathy and migraine (Sci Rep 2019;9:17280). Read More

Progression independent of relapses (PIRA) in MS


A new term in MS research that has emerged in recent years is PIRA, or progression independent of relapse activity. It purports to quantify the proportion of disability worsening due to non-inflammatory neurodegenerative processes. However, the new metric has its shortcomings and the methodology used to quantify PIRA has varied since the concept first appeared in 2017. Read More




B (as in billion) cells
Novel therapies, new chapters
SDMT revisited

The year 2019 saw important changes in how multiple sclerosis is being managed in an a increasingly complex therapeutic landscape (reviewed in Cree et al. Curr Opin Neurol 2019;32:365-377). The tectonics of that landscape are also shifting as new drugs are approved, generic formulations become available and the hothouse regulatory environment cools. Read More